Date of Award
Master of Science
Cisplatin, a chemotherapeutic agent, initiates cell death through various methods that include mtDNA damage during cell replication and produces damaging pro-inflammatory cytokines. This can result in long-term chemotherapy-related cognitive impairment (CRCI). Fluoxetine (FLX) is a selective serotonin reuptake inhibitor widely used in patients with anxiety and mood disorders. Published studies report that FLX could sensitize cancer cells to chemotherapy treatment and assist in attenuating CRCI. The aim of this study was to assess the ability of FLX to sensitize cancer cells to cisplatin treatment as well as the ability to attenuate cisplatin-induced cognitive impairment. Combined treatment of cisplatin +FLX was able to sensitize different cancer cell lines to treatment with cisplatin. In addition, mice treated with FLX performed significantly better when considering the response accuracy of the last three trials, regardless of criteria. These results suggest that FLX could have had a positive effect on the level of task difficulty and could improve working memory in mice.
Delgado, Xochitl, "FLUOXETINE AS A NOVEL TREATMENT TO ATTENUATE CISPLATIN-INDUCED COGNITIVE IMPAIRMENT" (2021). All NMU Master's Theses. 688.
Justification for Restricting Access
We plan to publish data from this thesis during the embargo period.
Available for download on Wednesday, November 11, 2026